Drugs /

carboplatin

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
carboplatin
Trade Name(s):
Ercar, Blastocarb, Nealorin, Platinwas, Paraplatin Aq, Novoplatinum, Carbosin, Paraplatin, Carbotec, Ribocarbo, Paraplat, Carbosol, Displata, Carboplat, and Paraplatine
NCI Definition [1]:
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for carboplatin

Carboplatin has been investigated in 387 clinical trials, of which 330 are open and 57 are closed. Of the trials investigating carboplatin, 4 are early phase 1 (4 open), 71 are phase 1 (49 open), 50 are phase 1/phase 2 (40 open), 174 are phase 2 (153 open), 6 are phase 2/phase 3 (6 open), 78 are phase 3 (74 open), 2 are phase 4 (2 open), and 2 are no phase specified (2 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for carboplatin clinical trials.

Breast carcinoma, non-small cell lung carcinoma, and primary peritoneal carcinoma are the most common diseases being investigated in carboplatin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Carboplatin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Carboplatin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating carboplatin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(ii), carboplatino, jm 8, Ercar, Ribocarbo, cis-diammine(1,1-cyclobutanedicarboxylato)platinum(ii), cis-diammine(cyclobutanedicarboxylato)platinum ii, 1,1-cyclobutanedicarboxylic acid platinum complex, carboplatin, 19314, cbdca - carboplatin, cis-diammine(1,1-cyclobutanedicarboxylato)platinum, jm-8, 41575-94-4, jm8, carboplatin, platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (sp-4-2), carboplatin (substance), diamminecyclobutanedicarboxylatoplatinum ii, (sp-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-o,o']platinum, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(ii), platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (sp-4-2)-, carboplatin hexal, carboplatin [chemical/ingredient], carboplatin (product), carboplatin, Platinwas, Paraplatine, Paraplatin AQ, Novoplatinum, Nealorin, Displata, Carbotec, Carbosol, Carbosin, Carboplat, Blastocarb, Paraplatin, Paraplat, cbdca, cis-diammine(cyclobutanedicarboxylato)platinum ii, 241240
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C1282
SNOMED ID [1]:
F-61B19

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.